Rapid decline in lung function is associated with more chronic respiratory symptoms, more severe small airway...

Accelerated lung function decline is an important factor affecting the development and prognosis of chronic obstructive pulmonary disease (COPD), but its clinical characteristics have not been determined. We conduct a retrospective study to assess the clinical characteristics of participants with accelerated lung function decline.

This study was based on the participants of Early Chronic Obstructive Pulmonary Disease (ECOPD) study enrolled in 2019-2020. Participants completed demographic data collection, COPD risk factor questionnaire, chronic respiratory symptom assessment, spirometry, impulse oscillometry (IOS) and computed tomography (CT) scan. We retrospectively sought lung function results from some of those who participated in the COPD epidemiology survey in 2012-2013 to obtain the rate of decline in lung function. Then we calculated the annual rate of decline based on the difference in lung function between 2012-2013 and 2019-2020. Accelerated lung function decline was defined as an annual decline in forced expiratory volume in one second (FEV₁) of ≥60 mL. The main results were grouped according to the rate of decline in pre-bronchodilator spirometry, and we also performed sensitivity analysis by grouping the post-bronchodilator spirometry. We examined including chronic respiratory symptoms, the degree of small airway dysfunction (SAD) respectively defined by spirometry, IOS, and CT, and the degree of emphysema, in participants with accelerated and non-accelerated lung function decline.

Among 298 participants with spirometry results in 2012-2013, 67 (22.5%) had an accelerated decline in pre-bronchodilator FEV₁. Participants with accelerated lung function decline were more likely to have chronic cough, chronic phlegm, and dyspnea (P<0.05) than those with non-accelerated lung function decline. They also had a higher proportion of spirometry-defined SAD, IOS-defined SAD, and CT-defined SAD and the severe degree of SAD. Participants who had an accelerated decline in lung function had more severe emphysema [inspiratory low attenuation area below -950 Hounsfield units: adjusted mean difference =2.5%, 95% confidence interval: 1.2-3.8%, P<0.001]. Results were maintained in sensitivity analyses grouped by the rate of decline in post-bronchodilator spirometry.

Participants with an accelerated decline in lung function had more severe chronic respiratory symptoms, structural lung changes, and SAD.